zelasudil

Zelasudil is a potent, highly selective, and orally active inhibitor of Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2). It targets ROCK2, which plays a key role in fibrosis and various cellular processes. Zelasudil is being developed primarily for the treatment of idiopathic pulmonary fibrosis (IPF) and has potential applications in other interstitial lung diseases and cancer-associated fibrosis. It is designed to avoid the hypotensive side effects associated with non-selective ROCK inhibitors by selectively targeting ROCK2 over ROCK1.

Other names

4-[5-[(4-cyclopropyl-1H-indazol-5-yl)amino]-1-methyl-1,2,4-triazol-3-yl]-N-(2,2-difluoroethyl)benzamide2365193-22-0